PhaseBio Pharmaceuticals (NASDAQ:PHAS) Stock Rating Upgraded by Zacks Investment Research – TechNewsObserver
PhaseBio Pharmaceuticals (NASDAQ:PHAS) Stock Rating Upgraded by Zacks Investment Research TechNewsObserver
Zacks Investment Research upgraded shares of PhaseBio Pharmaceuticals (NASDAQ:PHAS) from a hold rating to a buy rating in a research note published on …
Source: Investment New Feed